*Aurinia Pharmaceuticals Inc.

Changing the course of autoimmune disease

Inspired by patients. Driven to make an impact.

Latest News

October 3, 2022 • 4:05pm EDT

Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Read Press Release View All News

September 20, 2022 • 4:05pm EDT

Aurinia Pharmaceuticals Announces Presentations at American College of Rheumatology (ACR) Convergence 2022

Read Press Release View All News

September 19, 2022 • 11:15am EDT

Aurinia Announces European Commission Approval of LUPKYNIS® (voclosporin) for the Treatment of Lupus Nephritis

Read Press Release View All News